Immunophotonics
Manufacturing · Missouri, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
4340 Duncan Ave Ste 212, Saint Louis, Mi...Phone Number
(314) 501-1919Website
www.immunophotonics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Immunophotonics
Immunophotonics, Inc. is a privately owned, clinical-stage biotech company pioneering the emerging field of Interventional Immuno-Oncology. IP-001, the first asset from the company's intellectual property platform, has the potential to transform a routine tumor ablation into a systemically active cancer immunotherapy in multiple solid tumor indications by activating a tumor-specific anticancer immune response. The company is in phase 2 development and is based in St. Louis, Missouri, USA with subsidiaries in Bern, Switzerland and Tianjin, China.Explore more
Immunophotonics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Immunophotonics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Immunophotonics has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Immunophotonics recently announced quarterly report
Click to see if Immunophotonics had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Immunophotonics, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Immunophotonics
Check out if Immunophotonics is spiking on competitors!
Product Launch: Get notified when Immunophotonics launches new products
Funding: Get notified immidiatlly once Immunophotonics has new funding data
Recommended Actions
Reach out to Masked Content who joined Immunophotonics as Masked Content
Find 2 more new buyers
Compare Similar Companies to Immunophotonics
Compare insights from companies similar to Immunophotonics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Immunophotonics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Immunophotonics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Immunophotonics.
Immunophotonics financials insights
Gather financial insights about Immunophotonics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2010
Private Equity
$550K
2014
Private Equity
$2.5M
Series A
$1.8M
2021
Debt
$111K
2022
Series B
$21.4M
2026
Series C
$10M
Immunophotonics Tech Stack
A closer look at the technologies used by Immunophotonics
Most Recent Scoops
Project
Research & Development, Safety, Medical Research, Pharmaceuticals, Clinical Operations
Funding
Project
Laboratory Operations, Medical Research, Operations
Funding
Funding
Immunophotonics News & Media
Data from Immunophotonics Phase 1b/2a Clinical Trial to Be Presented at ASCO 2026
By activating systemic adaptive immunity, IP 001 may enable immune effector cells to identify and eliminate tumor cells throughout the body. SAINT LOUIS, MO, UNITED STATES, May 19, 2026 /EINPresswire.com/ -- Immunophotonics, Inc., a clinical-stage …Immunophotonics Secures European Patent Protecting Use of Lead Asset in Combination with Checkpoint Inhibitors
Additional intellectual property protection reinforces the strategic value of IP-001 and supports ongoing clinical development efforts. SAINT LOUIS, MO, UNITED STATES, February 24, 2026 /EINPresswire.com/ -- Immunophotonics, Inc., a clinical-stage …Immunophotonics Appoints Richard M. Levenson, M.D. to Board of Directors
SAINT LOUIS, MO, UNITED STATES, November 25, 2025 /EINPresswire.com/ -- Immunophotonics, Inc., a clinical-stage biotech company focused on developing novel Immune-stimulating drugs to augment routine tumor destruction techniques, has announced the …Immunophotonics and Swiss Cancer Institute Complete SAKK 66/17 Phase 1b/2a Multicenter Clinical Trial for Treatment of Solid Tumors
ST. LOUIS, Aug. 21, 2025 /PRNewswire/ -- Immunophotonics, Inc., a clinical-stage biotech company focused on developing novel immune-stimulating drugs to augment routine tumor destruction techniques, announced the completion of its multicenter clinical trial (SAKK 66/17) conducted in...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Immunophotonics
Sign Up For FreeTo access detailed company insights
Immunophotonics, Inc. is a privately owned, clinical-stage biotech company pioneering the emerging field of Interventional Immuno-Oncology. IP-001, the first asset from the company's intellectual property platform, has the potential to transform a routine tumor ablation into a systemically active cancer immunotherapy in multiple solid tumor indicat... Read More
